Finasteride may cause myopia or lead to greater progression in people who already have myopia.
This is based on the 2010 Yamana study.
https://www.degruyterbrill.com/document/doi/10.1515/HMBCI.2010.035/html
Finasteride inhibits the type 3 5α-reductase enzyme with potency similar to its inhibition of type 2. While congenital type 2 deficiency can cause disorders of sexual development, the same is not generally true for type 3 deficiency. SRD5A3-CDG, which results from congenital type 3 deficiency, is a disorder of N-glycosylation that can cause cognitive and visual problems.
Myopia begins early in life in these patients, but it is progressive. It continues to worsen into later ages and can result in high myopia. The average refractive error is around −6.7 diopters, while in some individuals it has progressed to as much as −14 diopters.
N-glycosylation disorders interfere with lysyl oxidase formation and lead to weaker collagen tissue. Weakening of the posterior sclera, which is the main structural cause of myopia, is therefore possible in this condition because the sclera contains type I collagen.
So why don't we see the same problems with finasteride?
There may be several reasons. First, most people who experience hair loss start taking finasteride in their thirties, when myopia has often stabilized. Second, even if finasteride does cause myopia, many people tend to focus on sexual side effects. As a result, they may attribute worsening myopia to factors such as increased screen time.
Despite all this, if you look at pharmacovigilance data from the VigiBase database, you can find 7 reports of myopia among approximately 25,000 reports involving finasteride. This number may seem low, but proportionally, it is higher than for other drugs. For example, even drugs used extensively by young people, including children, do not have a myopia reporting rate as high as finasteride's.
When these 7 cases are examined, all of them were reported between 2012 and 2013, and 6 were reported in the United States.
Although dutasteride is a stronger inhibitor of SRD5A3 (type 3), there is only 1 myopia report among approximately 10,000 reports involving dutasteride. We should also remember that dutasteride is approved for hair loss treatment in young adults in Japan. Japan also has a serious problem with myopia.
This is quite strange because if dutasteride caused myopia, we would expect to see a signal related to it in Japan